These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1479 related items for PubMed ID: 31942875

  • 1. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 2. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J, Egolum U, Parker S, Andrews E, Ombengi D, Ling H.
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [Abstract] [Full Text] [Related]

  • 3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y.
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [Abstract] [Full Text] [Related]

  • 4. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
    Capovilla TM, Lalario A, Rossi M, Porcari A, Aimo A, Limongelli G, Emdin M, Merlo M, Sinagra G.
    Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
    [Abstract] [Full Text] [Related]

  • 5. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN.
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827
    [Abstract] [Full Text] [Related]

  • 6. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J.
    Am J Cardiol; 2021 Jun 01; 148():146-150. PubMed ID: 33667442
    [Abstract] [Full Text] [Related]

  • 7. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
    Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K.
    Circ J; 2019 Dec 25; 84(1):15-17. PubMed ID: 31735731
    [Abstract] [Full Text] [Related]

  • 8. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    Circ Heart Fail; 2017 Jun 25; 10(6):. PubMed ID: 28611125
    [Abstract] [Full Text] [Related]

  • 9. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ.
    Circ Heart Fail; 2022 Jan 25; 15(1):e008193. PubMed ID: 34923848
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN, Deeks ED.
    Drugs; 2019 Jun 25; 79(8):863-874. PubMed ID: 31098895
    [Abstract] [Full Text] [Related]

  • 13. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F, Volpe R, Pastorelli F, Bianchi A, Vella A, Rapezzi C, Mascalchi M.
    J Stroke Cerebrovasc Dis; 2018 Sep 25; 27(9):e212-e214. PubMed ID: 29779881
    [Abstract] [Full Text] [Related]

  • 14. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T, Inomata T, Kaida T, Iida Y, Ikeda Y, Nabeta T, Ishii S, Maekawa E, Naruke T, Koitabashi T, Kitamura E, Sekijima Y, Ako J.
    Cardiology; 2017 Sep 25; 137(2):74-77. PubMed ID: 28152524
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
    Tess DA, Maurer TS, Li Z, Bulawa C, Fleming J, Moody AT.
    Amyloid; 2023 Jun 25; 30(2):208-219. PubMed ID: 36399070
    [Abstract] [Full Text] [Related]

  • 18. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y, Baranczak A, Helmke S, Teruya S, Horn EM, Maurer MS, Kelly JW.
    Amyloid; 2015 Jun 25; 22(3):175-80. PubMed ID: 26193961
    [Abstract] [Full Text] [Related]

  • 19. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T, Oikawa M, Amami K, Kanno Y, Yokokawa T, Misaka T, Yamada S, Kunii H, Nakazato K, Ishida T, Takeishi Y.
    Int Heart J; 2019 Nov 30; 60(6):1441-1443. PubMed ID: 31666456
    [Abstract] [Full Text] [Related]

  • 20. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H, Hashimoto T, Kawamura S, Hiroe M, Yamashita T, Ando Y, Yokochi T.
    J Med Case Rep; 2018 Dec 16; 12(1):370. PubMed ID: 30553273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.